Gastroparesis is a condition where the stomach empties food into the small intestine too slowly, often due to nerve damage affecting stomach muscle contractions.
Ranked by community outcomes, then evidence grade, Health Voice mentions, and recency.
Why it may help Gastroparesis: Stimulates gastric emptying
Elimination diet restricting fermentable carbohydrates (FODMAPs) shown to reduce IBS symptoms in most patients.
Deglycyrrhizinated licorice for ulcers and GERD without BP effect.
Why it may help Gastroparesis: Digestive enzymes may help manage gastroparesis by breaking down food more efficiently, thereby reducing the burden on a slow-emptying stomach and improving nutrient absorption.
Why it may help Gastroparesis: Artichoke extract may alleviate gastroparesis symptoms by stimulating bile flow and promoting gastrointestinal motility, which can help improve the rate of gastric emptying.
Why it may help Gastroparesis: Fennel may help alleviate gastroparesis symptoms by acting as a carminative, reducing gas and bloating, and potentially stimulating smooth muscle contractions to improve gastric motility.
Why it may help Gastroparesis: Repletes deficiencies from poor intake
Demulcent herb (Ulmus rubra) traditionally used to soothe GI mucosa.
Mucilaginous herb soothing GI and respiratory mucosa.
Why it may help Gastroparesis: Eases muscle and nerve function
Why it may help Gastroparesis: Calms upper GI symptoms
Why it may help Gastroparesis: Eases nausea and discomfort
Why it may help Gastroparesis: Helps diabetic gastroparesis
Why it may help Gastroparesis: Supports overall gut function
Active B12 form essential for nerve function and red blood cell production.
Community outcomes
Self-reported by community members · not medical advice.
Self-reported community outcomes. Not medical advice. Requires at least three reports per remedy to surface.
Community outcome data is still being collected for this ailment.
Be the first to share your experience →As more members share outcomes, RemedyAtlas will show which remedies helped people with similar conditions, symptoms, goals, and lab patterns.
Structured experience reports from people managing this condition. Not medical advice.
You can share without an account — we'll send a one-time code to verify your email. Or sign in.
Loading posts…
Community Discussions
How global health authorities view Gastroparesis.
Major health organizations like the Mayo Clinic and NIH acknowledge gastroparesis as a challenging condition, primarily managed through dietary changes and conventional medications. While they emphasize the importance of lifestyle modifications, there is generally limited endorsement of specific natural remedies for direct treatment of gastroparesis due to a lack of robust clinical trials. They typically advise caution with supplements and herbs, recommending discussion with a healthcare provider due to potential interactions with medications or underlying conditions. The focus remains on managing symptoms and addressing underlying causes, such as diabetes.
Indexed studies for Gastroparesis, grouped by source type and quality.
Filter by source type
Pooled analyses across multiple human trials.
Eckhardt D, Elshafei M, Fechner K, Diener MK, Hüttner FJ · The British journal of surgery · 2025
Gastroparesis is a chronic gastric motility disorder characterized by delayed gastric emptying in the absence of mechanical obstruction. Patients often experience nausea, vomiting, bloating, and early satiety. Several treatment options exist, including dietary changes, pharmacological agents, botulinum toxin injection, gastric electrical stimulation (GES), pyloroplasty, and gastric per-oral endoscopic myotomy (G-POEM). However, comparative effectiveness data are limited. A systematic review and network meta-analysis (NMA) was conducted to evaluate the relative effectiveness of interventions for gastroparesis. A literature search in PubMed, Google Scholar, and Cochrane CENTRAL (1982 to 31 May 2024) identified studies involving adults with scintigraphically confirmed gastroparesis and symptom assessment using the Gastroparesis Cardinal Symptom Index (GCSI) or Total Symptom Score (TSS). A DerSimonian-Laird random-effects meta-analysis and NMA with standardized mean differences were perfo
Varghese C, Lim A, Daker C, Sebaratnam G, Gharibans AA, Andrews CN · The American journal of gastroenterology · 2024
Gastroparesis is a debilitating gastroduodenal disorder for which gastric peroral endoscopic myotomy (GPOEM) has emerged as an efficacious treatment option. However, response to GPOEM varies between 50% and 80%, such that preoperative predictors of treatment success are needed to guide patient selection. We performed a systematic review to identify predictors of clinical and functional response to GPOEM among adult patients with gastroparesis (PROSPERO: CRD42023457359). MEDLINE, Embase, and CENTRAL databases were searched systematically for studies reporting outcomes after GPOEM in September 2023. A narrative synthesis of predictive factors on univariable and multivariable analysis was performed with consideration of response rates through meta-analysis and evaluation of discrimination if prognostic models were developed. Risk Of Bias In Non-randomized Studies - of Exposures (ROBINS-E) was used for risk of bias assessment. Of 1899 articles reviewed, 30 were included. The GPOEM respon
Epidemiology and Healthcare Utilization in Patients With Gastroparesis: A Systematic Review.
Dilmaghani S, Zheng T, Camilleri M · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2023
The authors performed a systematic review of epidemiologic data to understand the prevalence, incidence, etiologies, and hospitalizations related to gastroparesis (GP). Studies of the epidemiology of GP published in all languages, years, and countries from 5 databases in January 2022 were studied using prespecified search strategies. Thirteen studies (data from 1994 to 2019) were included. All but one study (from the United Kingdom) were based in the United States. Prevalence of definite GP (symptoms plus delayed gastric emptying) ranged from 13.8 to 267.7 per 100,000 adults, and incidence was 1.9-6.3 per 100,000 person-years. The estimated 10-year cumulative incidence of GP in type 1 diabetes (DM) and type 2 DM was 5.2% and 1.0%, respectively. Across studies, GP was more common among female patients and those with DM. Rates of hospitalizations and emergency department visits for GP are increasing, ranging from 2- to 18-fold over approximately 2 decades. Mortality rates for patients
Structured reviews of the full body of evidence (incl. Cochrane).
Efficacy of vagus nerve stimulation in gastrointestinal disorders: a systematic review.
Veldman F, Hawinkels K, Keszthelyi D · Gastroenterology report · 2025 · n=644
Dysfunction of the vagus nerve has been suggested as a contributing factor in various gastrointestinal disorders, prompting interest in vagus nerve stimulation (VNS) as a non-pharmacological therapy. We performed a systematic review to determine the efficacy of invasive and non-invasive VNS in gastrointestinal disorders, including inflammatory bowel disease (IBD), irritable bowel syndrome (IBS), functional dyspepsia (FD), functional constipation, gastroesophageal reflux disease, and gastroparesis. We applied a systematic search of the literature in the PubMed, Embase, Web of Science, and Cochrane Library databases in order to identify studies comparing VNS with an adequate control condition (sham stimulation) in patients with gastrointestinal disorders. The primary outcome was adequate symptom relief. Methodological quality was evaluated using the revised Cochrane risk-of-bias tool. Meta-analyses were not performed due to study heterogeneity. Seven randomized controlled trials investig
Bachmann KF, Jenkins B, Asrani V, Bear DE, Bolondi G, Boraso S · Critical care (London, England) · 2024 · n=285
Gastrointestinal (GI) dysfunction is common in critically ill patients and associated with poor outcomes. There is a lack of standardised methods for daily monitoring of GI function. COSMOGI aimed to develop a Core Outcome Set (COS) for daily monitoring of GI function to improve consistency and comparability in future studies in critically ill patients. A modified Delphi consensus process engaging healthcare providers, clinical researchers, and patient representatives was performed. A systematic review identified existing parameters to monitor GI function, informing the development of potential outcomes. In Stage 1, participants rated outcomes (i.e., variables used for daily monitoring). In Stage 2, they refined and agreed on the definitions for the selected outcomes. The COS was ratified through consensus meetings. 368 individuals registered for the Delphi process. 285 participants (77.4%) completed Stage 1, and 181 participants (63.5%) completed Stage 2. From 77 potential outcomes,
Masclee GMC, Keszthelyi D, Conchillo JM, Kruimel JW, Bouvy ND, Masclee AAM · Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery · 2023
Management of refractory gastroparesis is challenging after diet, prokinetics, and long-term nutritional support have failed. In this review, the efficacy and safety of surgical interventions (sleeve gastrectomy and Roux-en-Y gastric bypass surgery) are evaluated systematically in patients with refractory gastroparesis. The PubMed, Embase, and Scopus databases were searched to identify relevant studies published up to June 2021. Outcome of interest was symptom improvement and gastric emptying. Nineteen studies with 222 refractory gastroparesis patients (147 Roux-en-Y gastric bypass, 39 sleeve gastrectomy, and 36 subtotal gastrectomy) were included. All studies reported symptom improvement postoperatively, particularly vomiting and nausea. Gastric emptying improved postoperatively in 45% up to 67% for sleeve gastrectomy and 87% for Roux-en-Y gastric bypass. The findings of our systematic review suggest that sleeve gastrectomy and Roux-en-Y gastric bypass surgery improve symptoms and gas
Controlled human studies with random assignment.
Clinical Characteristics of Autoimmune Gastroparesis and Response to Immunomodulation.
Simons M, Loesch J, Hamza E, Brown JT, Lembo A, Cline M · Journal of clinical gastroenterology · 2025
Autoimmune factors may be involved in the development of gastroparesis, a subtype known as autoimmune gastrointestinal dysmotility (AGID). Small open label studies in AGID have demonstrated intravenous immunoglobulin (IVIG) therapy may lead to improvement in symptoms and gastric emptying. We aimed to evaluate the effects of IVIG therapy on symptom severity in patients with gastroparesis. We conducted a retrospective case series involving patients with AGID through medical chart review. All patients had evidence of delayed gastric emptying through gastric scintigraphy (GES) and had evidence of autoimmune dysfunction through seropositive antibody bloodwork, including glutamic acid decarboxylase (GAD), neuronal voltage-gated calcium channel, acetylcholine receptor, and neuronal voltage gated potassium channel autoantibodies. All patients received at least 12 weeks of IVIG therapy. Gastroparesis Cardinal Symptom Index (GCSI) scores were collected pre-IVIG and post-IVIG treatment. We anal
Zhu Y, Sarosiek I, Sun Y, Yin J, Abell T, Nojkov B · Neurogastroenterology and motility · 2025
Gastroparesis is common in patients with diabetes. However, treatment options for diabetic gastroparesis are limited. Transcutaneous electrical acustimulation (TEA), a noninvasive method of delivering electrical stimulation via surface electrodes placed at certain acupuncture points that are in the vicinity of peripheral nerves, has been reported to exert therapeutic effects in patients with gastroesophageal reflux, functional dyspepsia, and constipation. The aim of this study was to explore the therapeutic potential of TEA for diabetic gastroparesis. Eighteen patients with diabetes were enrolled in a single-center, placebo-controlled, randomized and crossover trial with TEA and sham-TEA. TEA was performed twice daily after lunch and dinner via acupoints, ST36 (below the kneecap in the vicinity of the peroneal, sciatic, and tibial nerves) and PC6 (wrist above the median nerve) for 4 weeks. A set of parameters previously reported to improve gastrointestinal motility was used for
Zheng T, BouSaba J, Taylor A, Dilmaghani S, Busciglio I, Carlson P · Clinical gastroenterology and hepatology : the official clinical practice journal of the American Gastroenterological Association · 2023 · n=44
Cannabis (delta-9-tetrahydrocannabinol), a nonselective cannabinoid-receptor agonist, relieves nausea and pain. Cannabidiol (CBD), a cannabinoid receptor 2 inverse agonist with central effects, also reduces gut sensation and inflammation. We compared the effects of 4 weeks of treatment with pharmaceutical CBD vs placebo in patients with idiopathic or diabetic (diabetes mellitus) gastroparesis. We performed a randomized, double-blinded, placebo-controlled study of CBD twice daily (Epidiolex escalated to 20 mg/kg/d; Jazz Pharmaceuticals, Dublin, Ireland) in patients with nonsurgical gastroparesis with delayed gastric emptying of solids (GES). Symptoms were assessed by the Gastroparesis Cardinal Symptom Index Daily Diary. After 4 weeks of treatment, we measured GES, gastric volumes, and Ensure (Abbott Laboratories, Abbott Park, IL) satiation test (1 kcal/mL, 30 mL/min) to assess volume to comfortable fullness and maximum tolerance. Patients underwent specific FAAH and CNR1 genotyping. St
Cohort, case-control, and cross-sectional human studies.
Lee A · Drugs · 2026
Tradipitant (NEREUS™) is a small molecule neurokinin-1 (NK-1) receptor antagonist being developed by Vanda Pharmaceuticals. NK-1 receptor activation and substance P release in the central nervous system leads to nausea and vomiting symptoms associated with motion sickness. Tradipitant received its first approval in the USA in December 2025 for the prevention of vomiting induced by motion in adults, and is also being developed for the treatment of gastroparesis and prevention of vomiting induced by GLP-1 receptor agonists. In phase III trials, tradipitant reduced the incidence of vomiting associated with motion sickness. This article summarizes the milestones in the development of tradipitant leading to this first approval for the prevention of vomiting induced by motion in adults.
Hanna-Jairala I, Tack J, Drossman DA · Neurogastroenterology and motility · 2026
Functional dyspepsia (FD) is a disorder of gut-brain interaction (DGBI), while gastroparesis (GP) is a motility disorder with overlapping upper gastrointestinal symptoms, including epigastric pain, postprandial fullness, early satiation, nausea, and vomiting, although their relative prevalence differs between conditions. First-line therapies, such as proton pump inhibitors and Helicobacter pylori eradication, often provide limited relief, prompting interest in alternative, mechanism-based treatments. To review the literature on the use of predominantly central and predominantly peripheral neuromodulators in FD and GP and to develop a symptom-directed therapeutic framework. We conducted a comprehensive review of the literature, synthesizing data from randomized controlled trials, observational studies, and clinical guidelines. Pharmacological profiles, pathophysiological targets, and safety considerations were evaluated. Predominantly central neuromodulators, particularly tricyclic a
Nutritional management in functional dyspepsia and gastroparesis.
Störsrud S, Algera JP, Törnblom H · Best practice & research. Clinical gastroenterology · 2025
Functional dyspepsia (FD) and gastroparesis (GP) are chronic upper gastrointestinal disorders in which symptoms are closely linked to food intake. However, dietary interventions remain insufficiently studied, and the clinical overlap between the two conditions poses challenges for study design and interpretation. This review summarizes current evidence on the impact of eating behaviors, specific diets and food items, and macronutrient composition on symptom generation in FD and GP, and considers how these findings may inform nutritional management strategies. While emerging data suggest potential dietary approaches, evidence-based recommendations remain limited. Well-designed randomized controlled trials with standardized diagnostic criteria, validated outcome measures, and integration of physiological biomarkers are urgently needed to establish effective, individualized dietary interventions for these disorders.
Registered ongoing or completed trials (ClinicalTrials.gov).
n=12 · NCT00492622 · COMPLETED · COMPLETED
The purpose of this study is to compare the blood drug levels of two prescribed medications, immediate-release omeprazole 40 mg powder and delayed-release omeprazole 40 mg capsule to determine which drug is better absorbed in patients with a slow stomach emptying (gastroparesis). Delayed-release omeprazole has a protective coating to prevent the drug omeprazole from being neutralized by stomach acid. Immediate-release omeprazole has sodium bicarbonate (antacid) which neutralizes the stomach acid, eliminating the need for a protective coating. Immediate-release omeprazole suspension may have a more rapid pharmacokinetic profile and greater overall drug absorption in gastroparesis.
n=12 · NCT04762719 · COMPLETED · COMPLETED
Macrophage-driven immune dysregulation has been shown to be involved in pathophysiology of diabetic gastroparesis. Currently, there are no non-invasive ways to study macrophage activation in humans. The researchers are trying to determine the utility of 11C-ER176 based PET-CT scanning to determine pro-inflammatory macrophage activation in gastric wall of patients with diabetic gastroparesis.
Transcutaneous Electroacupuncture for Gastroparesis
n=26 · NCT01469286 · COMPLETED · COMPLETED
Gastroparesis is a common disease defined as delayed emptying of the stomach. It is present in at least 20% of about 150 million patients with diabetes worldwide and in more than 20% of patients with functional dyspepsia that affects about 10%-25% of the general population. Gastroparesis is a refractory disease with a lack of therapeutic options. Common symptoms of gastroparesis include nausea, vomiting, early satiety and abdominal bloating. Electroacupuncture (EA) is a combined procedure with acupuncture and electrical current stimulation instead of manual manipulations of the needles. Recent studies in our lab with EA or transcutaneous EA (TEA) have suggested a therapeutic role of EA or TEA for gastric motility disorders. Improvement has been observed with EA or TEA in gastric emptying as well as dyspeptic symptoms. In this project, a micro-stimulator is designed and developed for the TEA therapy. The micro-stimulator is small enough so that it can be attached to the skin next to the stimulation electrodes and therefore the patient can resume normal daily activity while being treated by TEA. This is not only attractive but also more effective since TEA can be performed more often and for longer durations. This exploratory project is designed to study the feasibility, efficacy and certain mechanisms of the proposed method of "wireless" TEA in patients with gastroparesis. Firstly the feasibility of the chronic use the proposed micro-stimulator will be studied. Secondly, the efficacy of the TEA in improving delayed gastric emptying and symptoms of gastroparesis will be investigated in a double-blinded crossover design in patients with diabetic or idiopathic gastroparesis. Thirdly, possible mechanisms involving pathogeneses of gastroparesis with TEA will be investigated.
Curated cross-source summaries (TRIP Database and similar).
NICE
NICE provides access to clinical guidelines, technology appraisals, and other guidance related to gastroparesis. While there isn't a dedicated guideline specifically titled 'Gastroparesis' from NICE, relevant information can be found through their search portal.
Conventional medical care for gastroparesis typically involves medications to stimulate stomach emptying (prokinetics) and antiemetics to control nausea and vomiting. Dietary counseling is a cornerstone of treatment. In severe cases, nutritional support via feeding tubes or gastric electrical stimulation may be considered. Regular monitoring and management of underlying conditions, especially diab
Latest News
Health Videos
This information is for educational purposes only and does not constitute medical advice. Gastroparesis is a serious condition requiring professional medical diagnosis and management. Always consult with a qualified healthcare provider before making any decisions about your health or treatment plan.
Found something that helped your gastroparesis?
Help others see what actually works.
Found something that helped your gastroparesis?
Real-world results help others choose what's worth trying.